Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...
When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
A Cracker Barrel board member who has drawn controversy over his DEI background has resigned, the company announced Thursday. Upon announcing that shareholders voted to elect nine of the company’s 10 ...
Employer-focused global fertility company Carrot announced a partnership with health-tracking ring maker Oura and continuous glucose monitoring company Dexcom to combine fertility and family-building ...
The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- Company: DexCom is a medical device company primarily focused on the design, ...
The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Dexcom, Inc. securities during the class period because the Company ...
The Magnum Ice Cream Company has concluded that the chair of its Ben & Jerry’s independent board “no longer meets the criteria” to serve after internal investigations, according to a securities filing ...
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback